ABSTRACT
OBJECTIVE: To observe the effect of moxibustion on the growth of tumor and expression of fibroblast growth factor receptor 1 (FGFR1) and vascular endothelial cell growth factor receptor 2 (VEGFR2) in mice with sarcoma, so as to explore its mechanisms underlying inhibiting sarcoma growth. METHODS: C57BL/6J mice (half male and half female) were inoculated with S180 sarcoma cells to form transplanted tumors, and divided into model control, medication and moxibustion groups, with 10 mice in each group. Moxibustion was applied to the transplanted tumor directly for 10 min, once a day for 14 days. After the treatment, Luminex liquid suspension chip was used to detect the contents of serum vascular endothelial growth factor (VEGF), FGFR1 and VEGFR2. The weight of the transplanted tumor was measured, and the expression of VEGF in the transplanted tumor was detected by immunohistochemistry, and the expression of FGFR1 and VEGFR2 mRNAs in the transplanted tumor was detected by fluorescence in situ hybridization. RESULTS: The tumor weight, VEGF immunoactivity, serum VEGF, VEGFR2 and FGFR1 contents, and expression levels of VEGFR2 and FGFR1 mRNAs in the transplanted tumor were significantly lower in the moxibustion group than in the model group (P<0.001, P<0.01, P<0.05). Compared with the model group, the tumor weight was remarkably lower in the medication group (P<0.001). Compared with the medication group, th VEGF immunoactivity and the contents of serum VEGF, VEGFR2 and FGFR1 were significantly lower in the moxibustion group ï¼P<0.01, P<0.05ï¼. H.E. staining showed a large number of red blood cells were observed in the microenvironment of the transplanted tumor in the moxibustion group rather than in the medication group. CONCLUSION: Moxibustion can inhibit the growth of tumor in mice with sarcoma, which may be related to its function in reducing the expression of FGFR1 and VEGFR2 to inhibit angiogenesis.
Subject(s)
Moxibustion , Sarcoma , Animals , Female , In Situ Hybridization, Fluorescence , Male , Mice , Mice, Inbred C57BL , Receptor, Fibroblast Growth Factor, Type 1/genetics , Sarcoma/genetics , Sarcoma/therapy , Tumor Microenvironment , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor Receptor-2/geneticsABSTRACT
Slab gain media with large aspect ratios were difficult to be adopted in ultrafast regenerative amplifiers (RAs) due to the obstacle of mode matching with the seed beam. We proposed that an unstable cavity could be employed to solve this difficulty by taking the advantage of its large fundamental mode volume. In this way, an Nd:YVO4 slab-based picosecond RA has been successfully demonstrated using a stable-unstable hybrid cavity. The maximum average output power of 10.5 W was achieved at the repetition rate of 10 kHz. The beam quality factor M2 was measured to be 1.54 in the stable direction and 2.26 in the unstable direction.
ABSTRACT
We have proposed a novel approach to realize a high-energy ultrafast optical parametric oscillator (OPO) by intracavity pumping in a regenerative amplifier. In this way, we have experimentally demonstrated an unprecedented pulse energy of 30.5 µJ from a 1.5-µm singly resonant synchronously pumped OPO at a pulse repetition rate of 10 kHz with a pulse width of 7.0 ps. To the best of our knowledge, this is the highest pulse energy from an ultrafast laser OPO.
ABSTRACT
A pulse width adjustable 1064 nm Q-switched cavity dumped Nd:YVO4 laser was realized for the first time, to the best of our knowledge, by rotating an intracavity quarter-wave plate (QWP) and a Pockels cell (PC). The pulse width adjustment range was 4.8-7.8 ns with a constant output power of 3.6 W, and it reached 4.8-13.5 ns for a lower output power of 1.3 W. The pulse width was dependent mostly on the rotating angle of the QWP and PC, but independent of the gain and pulse repetition rate.
